Catriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total transaction of $498,700.00. Following the sale, the insider now owns 95,648 shares of the company’s stock, valued at approximately $4,769,965.76. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Catriona Yale also recently made the following trade(s):

• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.11, for a total transaction of $264,144.14.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock traded up $1.26 on Friday, hitting $51.84. The stock had a trading volume of 851,969 shares, compared to its average volume of 1,680,119. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -13.82 and a beta of -0.11. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The company’s 50 day moving average price is $36.56 and its 200 day moving average price is $31.49. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after acquiring an additional 446 shares during the period. Summit Investment Advisors Inc. lifted its stake in Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after buying an additional 450 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Akero Therapeutics by 8.5% in the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock valued at $220,000 after buying an additional 621 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Akero Therapeutics by 1.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company’s stock valued at $1,153,000 after buying an additional 637 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Akero Therapeutics by 5.0% in the 4th quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock valued at $584,000 after buying an additional 1,000 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on AKRO. Morgan Stanley increased their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group increased their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. HC Wainwright raised their target price on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Citigroup raised their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Finally, UBS Group raised their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.